MEDIA ALERT

OBESITY DRUGS COMPARATIVE SAFETY REVIEW

ALLI, BELVIQ, CONTRAVE, PHENTERMINE, QSYMIA, XENICAL

SANTA ROSA, Calif., October 6, 2014 – AdverseEvents, Inc., a healthcare informatics company, released at the Academy of Managed Care Pharmacy Nexus Conference in Boston, a comparative safety review of approved obesity drug treatments, in response to the controversial FDA approval of Contrave (**Orexigen Therapeutics**). Obesity drug treatments have long been contentious -- in 14 years only 3 drugs have received FDA approval and stayed on the US Market. Several of these drugs are classified as Schedule IV controlled substances and all have notable side effects. On September 10th, the FDA granted approval of the new chronic weight-loss drug, Contrave (naltrexone and bupropion extended-release). Due to Contrave's safety profile (Black Box Warning – suicide/neuropsychiatric reactions), significant public safety issues are being raised.

In response to these safety concerns, AdverseEvents, Inc., has generated the accompanying report to highlight and contrast the safety profiles for Contrave and five other competing drug treatments for obesity.

Highlights include:

- **Drug comparison listing of Outcomes including Death, Hospitalization and Disability**
- **RxScore comparisons –highest (Desoxyn) and lowest (Qsymia) safety profiles**
- **Comparison of on-label Contrave adverse events to reported adverse events for Belviq and Qsymia**
- **Off-label adverse events that may trigger future pharmacovigilance action for Qsymia**

Drugs included in this report include:

- **Alli (orlistat), GlaxoSmithKline**
- **Belviq (lorcaserin hydrochloride), Eisai, Arena Pharmaceuticals**
- **Contrave (bupropion hydrochloride; naltrexone hydrochloride), Orexigen Therapeutics**
- **Phentermine (phentermine)**
- **Qsymia (phentermine hydrochloride; topiramate), Vivus**
- **Xenical (orlistat), Roche**

Click here to view the Report

ABOUT ADVERSE EVENTS, INC.

AdverseEvents, Inc. (AEI) is a California-based healthcare informatics company that improves patient safety and reduces systemic healthcare costs through comprehensive data mining and analysis of post-marketing drug side

effect data. AEI is one of the foremost research authorities on drug side effects – publishing comparative drug studies, industry white papers, topical special reports, and platform validating research papers in leading academic journals. AEI makes post-marketing drug safety data accessible, actionable, and predictable.